Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its target price upped by HC Wainwright from $15.00 to $20.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald […]
Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its price objective increased by HC Wainwright from $15.00 to $20.00 in a research note released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald restated an […]
/PRNewswire/ Technavio categorizes the global gene therapy market size as estimated to increase by USD 4,613.9 million between 2022 and 2027. The market s.
Poseida Therapeutics Inc PSTX released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell…